Cardio?renal?metabolic syndrome has emerged as a defining construct in modern cardiovascular medicine. The rising prevalence of obesity, type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) has created a clinical environment in which cardiovascular disease rarely occurs in isolation. Instead, patients present with a constellation of metabolic, renal, and cardiac abnormalities that interact in complex and mutually reinforcing ways. The American Heart Association (AHA) recently formalized this interconnected framework as cardiovascular?kidney?metabolic (CKM) syndrome, underscoring its clinical importance and the need for integrated care pathways [1].
Despite this interconnected biology, clinical care remains fragmented. Cardiologists focus on heart failure and atherosclerosis, nephrologists on renal decline and electrolyte disturbances, and endocrinologists on glycemic control and metabolic risk. This siloed approach obscures the shared mechanisms that drive disease progression and often leads to delayed recognition and suboptimal treatment. As evidence accumulates across disciplines, it is increasingly clear that CKM syndrome requires a unified conceptual framework and an integrated therapeutic strategy.
This review synthesizes current knowledge on CKM syndrome, emphasizing the epidemiologic burden, mechanistic underpinnings, diagnostic challenges, and therapeutic opportunities. Our goal is to provide clinicians and researchers with a cohesive narrative that reflects the complexity of this syndrome and highlights the need for coordinated, phenotype?driven care.
Epidemiology and Clinical Burden
The epidemiologic footprint of CKM syndrome is vast and expanding. Individuals with T2DM face a markedly elevated risk of cardiovascular disease, with nearly three?quarters developing cardiac pathology over their lifetime. [2] CKD, even in its earliest stages, amplifies this risk, accelerating both cardiovascular events and renal decline. [3] Heart failure, particularly heart failure with preserved ejection fraction (HFpEF), has become a hallmark of metabolic and renal dysfunction, with obesity and insulin resistance serving as upstream drivers of myocardial stiffness and microvascular impairment. [4]
The distribution and presentation of CKM depends on multiple factors. Young adults are increasingly developing obesity?related metabolic disease, shifting the age distribution of CKM syndrome downward. [5] In low?resource settings, limited access to preventive care and advanced therapies further exacerbates disease progression.
Clinically, CKM syndrome is associated with higher hospitalization rates, increased healthcare costs, and reduced quality of life. [6] Patients often experience rapid progression of both cardiac and renal disease, with each organ system amplifying dysfunction in the others. This interconnected burden underscores the need for early recognition and integrated management.
Pathophysiology: A Unified Disease Network
The pathophysiology of CKM syndrome is best understood as a network of mutually reinforcing processes rather than a linear cascade. Metabolic dysfunction often serves as the upstream initiator. Insulin resistance impairs endothelial nitric oxide production, promotes vascular stiffness, and alters renal sodium handling, creating a milieu that favors hypertension and glomerular hyperfiltration. Visceral adiposity contributes additional layers of complexity, as adipose tissue becomes a source of pro?inflammatory cytokines and ectopic fat deposition disrupts normal cellular function in the liver, kidney, and heart. [1,7]
As renal impairment develops, it amplifies cardiovascular risk through the accumulation of uremic toxins, activation of the renin–angiotensin–aldosterone system, and heightened sympathetic activity. These processes promote vascular calcification, myocardial fibrosis, and left ventricular remodeling. Even modest reductions in glomerular filtration rate are associated with increased risk of heart failure and arrhythmias, highlighting the kidney’s role as a disease accelerator. [8]
Cardiovascular dysfunction, particularly HFpEF, represents the final common pathway of CKM syndrome. Myocardial fibrosis, microvascular rarefaction, and impaired nitric oxide signaling collectively reduce ventricular compliance and impair diastolic filling. Congestion feeds back onto the kidneys by elevating venous pressures and reducing renal perfusion, worsening sodium retention and neurohormonal activation. [9] The result is a self?perpetuating cycle in which metabolic, renal, and cardiac dysfunction reinforce one another.
|
Mechanism |
Cardiovascular Impact |
Renal Impact |
Metabolic Impact |
|
Insulin resistance |
Endothelial dysfunction, HFpEF |
Glomerular hyperfiltration |
Hyperglycemia, lipotoxicity |
|
Chronic inflammation |
Atherosclerosis, fibrosis |
Tubulointerstitial injury |
Adipose inflammation |
|
RAAS activation |
Hypertension, LV remodeling |
Proteinuria, CKD progression |
Worsened insulin resistance |
|
Sympathetic overdrive |
Arrhythmias, HF |
Reduced renal perfusion |
Impaired glucose metabolism |
|
Oxidative stress |
Microvascular rarefaction |
Tubular damage |
β?cell dysfunction |
Table 1: Key Pathophysiologic Mechanisms Linking the Cardio?Renal?Metabolic Triad
Staging of CKM Syndrome
The American Heart Association’s CKM staging framework provides a structured way to conceptualize the progressive, interconnected nature of metabolic dysfunction, kidney disease, and cardiovascular pathology. [1,7] Rather than treating these conditions as isolated entities, the CKM stages describe a continuum of multisystem risk, beginning with ideal health and culminating in overt cardiovascular disease. This approach supports earlier identification of high?risk individuals and encourages timely, phenotype?appropriate intervention.
Stage 0 represents optimal cardiometabolic health, a state that has become increasingly uncommon as obesity and metabolic dysfunction rise globally. [110] Stage 1 captures early metabolic risk, often subtle but biologically meaningful, such as mild dysglycemia, elevated blood pressure, or early weight gain. Stage 2 reflects established metabolic disease, including type 2 diabetes or obesity, even when kidney function and cardiovascular structure remain normal.
Progression to Stage 3 marks the onset of kidney involvement or subclinical cardiovascular abnormalities, such as albuminuria, reduced eGFR, left ventricular hypertrophy, or coronary artery calcification [11] . Finally, Stage 4 denotes overt cardiovascular disease, including heart failure, myocardial infarction, stroke, or peripheral artery disease. [12] At this stage, metabolic and renal dysfunction often coexist and amplify one another, underscoring the need for coordinated, multidisciplinary care.
This staging system reframes cardiometabolic care by emphasizing early detection, progressive risk, and integrated management, aligning clinical practice with the biology of CKM syndrome.
|
Stage |
Definition |
Key Features |
Clinical Focus |
|
Stage 0 |
Optimal cardiometabolic health |
Normal weight, normal BP, normal glucose, normal kidney function |
Primordial prevention; lifestyle maintenance |
|
Stage 1 |
Early metabolic risk |
Overweight, pre?hypertension, pre?diabetes, dyslipidemia |
Lifestyle intervention; risk?factor modification |
|
Stage 2 |
Established metabolic disease |
Type 2 diabetes, obesity, metabolic syndrome; normal kidney & CV structure |
Pharmacologic therapy (GLP?1 RA, SGLT2i); aggressive risk reduction |
|
Stage 3 |
Kidney and/or subclinical cardiovascular involvement |
Albuminuria, eGFR <60; LVH, CAC, abnormal strain imaging |
Multidisciplinary care; therapies with cardio?renal benefit |
|
Stage 4 |
Clinical cardiovascular disease |
HF (esp. HFpEF), MI, stroke, PAD; often with CKD and metabolic disease |
Guideline?directed therapy; volume management; integrated specialty care |
Table 2: Stages of CKM Syndrome
Diagnostic Challenges and Phenotyping
Despite its prevalence, CKM syndrome remains underrecognized. Traditional risk calculators underestimate cardiovascular risk in patients with diabetes or CKD because they fail to account for nonlinear interactions between metabolic and renal factors. Biomarkers commonly used in cardiology require careful interpretation in the context of reduced renal clearance, while renal biomarkers such as albuminuria provide valuable prognostic information but are not routinely integrated into cardiovascular risk assessment. [13]
Imaging modalities also have limitations. Standard echocardiography may not detect early microvascular dysfunction or subtle myocardial fibrosis, while renal imaging rarely captures the hemodynamic consequences of cardiac congestion. [14] Emerging techniques such as strain imaging and PET?MRI hybrid imaging offer promise but are not yet widely available.
Phenotyping may offer a path forward. Patients with CKM syndrome often fall into recognizable patterns such as HF?dominant, CKD?dominant, metabolic?dominant, or mixed phenotypes, each with distinct therapeutic implications. A phenotype?based approach may improve risk stratification and guide therapy selection. [15]
Therapeutic Landscape: From Organ?Specific to Integrated Care
The therapeutic paradigm for CKM syndrome is shifting from organ?specific treatment to integrated, tri?organ strategies. SGLT2 inhibitors have emerged as the first true CKM therapy, demonstrating benefits across cardiovascular, renal, and metabolic domains. Their mechanisms, including natriuresis, improved renal oxygenation, reduced inflammation, and enhanced myocardial energetics, reflect the interconnected nature of the syndrome. [16]
GLP?1 receptor agonists offer complementary benefits, particularly in metabolic?dominant phenotypes, with significant weight loss and reduced atherosclerotic events. [17] Non?steroidal mineralocorticoid receptor antagonists such as finerenone provide anti?inflammatory and anti?fibrotic effects that benefit both the heart and kidneys. [18] Lifestyle interventions, including structured weight loss and bariatric surgery, remain foundational and can produce profound improvements across all three organ systems. [19]
Emerging therapies, including dual incretin agonists, anti?inflammatory agents targeting IL?6 and NLRP3, and metabolic modulators of myocardial energetics, hold promise for further expanding the therapeutic options. [20]
|
Therapy Class |
Cardiovascular Benefit |
Renal Benefit |
Metabolic Benefit |
|
SGLT2 inhibitors |
↓ HF hospitalization |
↓ CKD progression |
↓ Glucose, ↓ weight |
|
GLP?1 RAs |
↓ ASCVD events |
Possible renal protection |
Significant weight loss |
|
Non?steroidal MRAs |
↓ CV events |
↓ Albuminuria |
Anti?inflammatory effects |
|
Dual incretin agonists |
Weight loss, improved HFpEF symptoms |
Under investigation |
Profound metabolic improvement |
|
Lifestyle interventions |
Improved HF symptoms |
Improved renal hemodynamics |
Weight loss, improved insulin sensitivity |
Table 3: Therapeutic Classes with Tri?Organ Benefits in CKM Syndrome
Clinical Integration: A New Model of Care
CKM syndrome demands a shift toward integrated, multidisciplinary care. Cardiologists, nephrologists, endocrinologists, primary care physicians, and nutritionists must collaborate to develop coordinated treatment plans. Phenotype?driven algorithms can guide therapy selection based on the degree of metabolic dysfunction, renal reserve, and cardiac phenotype.
Artificial intelligence and multi?omics profiling offer opportunities for precision medicine, enabling earlier identification of high?risk phenotypes and more tailored therapeutic strategies. As evidence accumulates, CKM syndrome may emerge as a distinct clinical entity with dedicated guidelines and tri?organ clinical trial endpoints.
Future Directions
Key priorities include establishing unified diagnostic criteria, developing integrated biomarkers and imaging tools, designing trials with tri?organ endpoints, and addressing disparities in access to metabolic therapies. Understanding sex?specific and age?specific phenotypes will be essential for refining treatment strategies. Ultimately, CKM syndrome represents a frontier in cardiovascular medicine, offering opportunities for innovation in both research and clinical care.
Cardio?renal?metabolic syndrome represents a transformative shift in how clinicians conceptualize cardiovascular disease. The triad of metabolic dysfunction, renal impairment, and cardiovascular pathology forms a unified disease process requiring integrated, phenotype?driven care. With the advent of SGLT2 inhibitors, GLP?1 receptor agonists, and emerging metabolic therapies, clinicians now have tools that address the syndrome at its root. The challenge ahead is to build systems of care and research frameworks that reflect this new reality.
Author Contributions: Aarushi Batra: Conceptualization, writing – original draft, writing – review & editing. Ashok Kumar: Writing – review & editing. All authors approved the final manuscript
None declared.
The authors declare no conflicts of interest.
[1] Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-Kidney-Metabolic Health: A presidential advisory from the American Heart Association. Circulation [Internet]. 2023 Oct 9;148(20):1606–35. Available from: https://doi.org/10.1161/cir.0000000000001184
[2] Chakraborty S, Verma A, Garg R, Singh J, Verma H. Cardiometabolic risk factors associated with Type 2 diabetes mellitus: a mechanistic insight. Clinical Medicine Insights Endocrinology and Diabetes [Internet]. 2023 Jan 1;16:11795514231220780. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10750528/
[3] Kotwal SS, Perkovic V. Kidney disease as a cardiovascular disease priority. Circulation [Internet]. 2024 Sep 23;150(13):975–7. Available from: https://doi.org/10.1161/circulationaha.124.068242
[4] Grilo RM, Falcão LM. Heart failure with preserved ejection fraction and chronic kidney disease: From pathophysiology to treatment. The American Journal of Cardiology [Internet]. 2025 Oct 22;258:287–301. Available from: https://doi.org/10.1016/j.amjcard.2025.10.013
[5] Iyer A, Sharma V, Dwivedi S. Exploring the impact of morbid obesity on cardiovascular and metabolic parameters in young individuals. International Journal of Diabetes in Developing Countries [Internet]. 2026 Mar 18; Available from: https://doi.org/10.1007/s13410-026-01640-z
[6] De Abreu AP, Drager LF, Almeida MQ, Bortolotto LA, Lopes HF. Cardiovascular-kidney-metabolic Syndrome: a current and urgent concept. Brazilian Journal of Nephrology [Internet]. 2025 Apr 1;47(2):e20240277. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12092022/
[7] Ndumele CE, Neeland IJ, Tuttle KR, Chow SL, Mathew RO, Khan SS, et al. A synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A scientific statement from the American Heart Association. Circulation [Internet]. 2023 Oct 9;148(20):1636–64. Available from: https://doi.org/10.1161/cir.0000000000001186
[8] Haase M, Müller C, Damman K, Murray PT, Kellum JA, Ronco C, et al. Pathogenesis of Cardiorenal Syndrome Type 1 in Acute Decompensated Heart Failure: Workgroup Statements from the Eleventh Consensus Conference of the Acute Dialysis Quality Initiative (ADQI). Contributions to Nephrology [Internet]. 2013 Jan 1;182:99–116. Available from: https://doi.org/10.1159/000349969
[9] Kanjanahattakij N, Sirinvaravong N, Aguilar F, Agrawal A, Krishnamoorthy P, Gupta S. High Right Ventricular Stroke Work Index Is Associated with Worse Kidney Function in Patients with Heart Failure with Preserved Ejection Fraction. Cardiorenal Medicine [Internet]. 2018 Jan 1;8(2):123–9. Available from: https://doi.org/10.1159/000486629
[10] Aggarwal R, Ostrominski JW, Vaduganathan M. Prevalence of Cardiovascular-Kidney-Metabolic syndrome stages in US adults, 2011-2020. JAMA [Internet]. 2024 May 8;331(21):1858. Available from: https://doi.org/10.1001/jama.2024.6892
[11] Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. The Lancet [Internet]. 2013 May 31;382(9889):339–52. Available from: https://doi.org/10.1016/s0140-6736(13)60595-4
[12] Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular disease in chronic kidney disease. Circulation [Internet]. 2021 Mar 15;143(11):1157–72. Available from: https://doi.org/10.1161/circulationaha.120.050686
[13] Harrison TG, James MT. CKD, Cardiovascular Risk Estimation, and Gaps in therapy: A shift to PREVENT. American Journal of Kidney Diseases [Internet]. 2025 May 16;86(1):4–6. Available from: https://doi.org/10.1053/j.ajkd.2025.04.004
[14] Carbone A, D’Andrea A, Sperlongano S, Tagliamonte E, Mandoli GE, Santoro C, et al. Echocardiographic assessment of coronary microvascular dysfunction: Basic concepts, technical aspects, and clinical settings. Echocardiography [Internet]. 2021 May 5;38(6):993–1001. Available from: https://doi.org/10.1111/echo.15059
[15] Tan CYH, Koh JYJ, Ang WW, Tan XM, Koh SWC, Lin W, et al. State-of-the-art digital phenotyping methods for cardiometabolic risk prevention and management: a scoping review. International Journal of Medical Informatics [Internet]. 2025 Oct 10;206:106133. Available from: https://doi.org/10.1016/j.ijmedinf.2025.106133
[16] Vallon V. State-of-the-Art-Review: Mechanisms of action of SGLT2 inhibitors and clinical implications. American Journal of Hypertension [Internet]. 2024 Jul 17;37(11):841–52. Available from: https://doi.org/10.1093/ajh/hpae092
[17] Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Frontiers in Endocrinology [Internet]. 2024 Jul 24;15:1431292. Available from: https://doi.org/10.3389/fendo.2024.1431292
[18] Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. European Heart Journal [Internet]. 2020 Sep 1;42(2):152–61. Available from: https://doi.org/10.1093/eurheartj/ehaa736
[19] Shahid I, Philip J, Avenatti E, Laddu D, Shapiro MD, Khera A, et al. Lifestyle Interventions in Cardiovascular-Kidney-Metabolic Syndrome JACC: Advances Expert Panel. JACC Advances [Internet]. 2025 Jun 1;4(6):101788. Available from: https://doi.org/10.1016/j.jacadv.2025.101788
[20] Muzurovi? E, Katsiki N, Vol?anšek Š, Plescia F, Rizzo M, Mantzoros CS. Emerging incretin- and multi-agonist-based treatments – the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond. Metabolism [Internet]. 2026 Jan 20;177:156494. Available from: https://doi.org/10.1016/j.metabol.2026.156494.
IJBMR -ISSN: 0976:6685. ©Copyright 2026 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Published by BioMedSciDirect Publications